SPRB Spruce Biosciences Inc

Citizens reiterated $SPRB Market Outperform-$144 and said -- The virtual Advance Sanfilippo Community Conference that wrapped yesterday (9/23) highlighted TA-ERT as the leading emerging therapy for MPS IIIB, with FDA commentary reinforcing the need for regulatory flexibility ahead of SPRB's expected 4Q26 BLA submission.

$SPRB this is obivously a tiny market overall, but I think its made even smaller by the way TA-ERT is administered (directly into the brain weekly) and the side effects. I'm guessing this is just a tiny little ultra rare market and these price targets in the 100+ range are likely to be a big bust

$SPRB Any catalyst in the remaining 2026? I am thinking about tax loss selling here. Average is $59 but running out of patience. JMO

$SPRB all these companies keep saying 120+ for this , but it's trading at $50 - it doesn't make sense.